Roivant's Explosive Growth: A Year of Breakthroughs and Record-Breaking Achievements
Roivant, a global biopharmaceutical company, has wrapped up an extraordinary fiscal year with a multitude of groundbreaking announcements and milestones. The recent Q4 2025 earnings call provided a comprehensive update on the company's progress, showcasing its unwavering commitment to innovation and patient care.
The quarter was marked by several pivotal moments, beginning with the awarding of Breakthrough Designation and Rare Therapy Designation for cutaneous sarcoidosis, a debilitating condition affecting thousands. This achievement underscores Roivant's dedication to identifying and addressing unmet medical needs, demonstrating its expertise in indication selection and development.
Additionally, the company announced Lupus-Related Protoporphyria (LPP) as an indication for brepocitinib, a cutting-edge treatment that has already shown promising results. The study is now enrolling participants, further solidifying Roivant's position as a leader in dermatological research.
One of the most significant data updates was presented by Matt Gline, CEO of Roivant, who highlighted the impressive ACR response rates achieved in the IMVT-1402 study for D2T RA. This clinically meaningful outcome has sparked widespread excitement within the medical community and beyond. Moreover, the company is now fully enrolled on CLE with top-line data expected in the second half of 2026.
While acknowledging that this quarter was indeed "wild" for Roivant, CEO Matt Gline expressed his pride in the company's execution momentum across its development portfolio. This sentiment was echoed by Drew Fromkin, CEO of Pulmovant, who underscored the importance of Roivant's partnerships and dedication to improving patient outcomes.
The quarter also witnessed the failure of the batoclimab studies in TED but noted a significant improvement in hyperthyroid patients, which has substantial implications for Roivant's ongoing Graves' disease research. Furthermore, the company successfully negotiated a $2.25 billion settlement with Moderna, with the first portion of the payment, $950 million, expected to be received in July.
As Roivant embarks on an even more transformative journey, numerous promising initiatives are on the horizon. These include launching brepocitinib in dermatomyositis by September 2026, initiating a phase III study in cutaneous sarcoidosis this year, and expecting NIU phase III top-line data in the back half of 2026. The company's commitment to advancing cutting-edge treatments is unwavering.
Roivant's remarkable growth and milestones serve as a testament to its dedication to innovation, patient care, and collaboration. As the company continues to drive progress across its development portfolio, it remains poised to deliver life-changing treatments to those who need them most.
